Wednesday, July 8, 2026

biotech · Multiple Myeloma · Multiple Myeloma (MM) · CCCC

C4 Therapeutics

C4 Therapeutics is a biotech organization headquartered in WATERTOWN, MA, USA. It trades on NYSE under ticker CCCC. Primary therapeutic focus areas include Multiple Myeloma, Multiple Myeloma (MM), Solid Tumors, Synovial

WATERTOWN, MA, USA HQ
2024 Founded
2 Employees
Public company Type
CCCC · NYSE Ticker
Company details
Status
Public
HQ
WATERTOWN, MA, USA
Founded
2024
Employees
2
Programs
4
Drugs
1
Patents
24
Clinical program

CFT8634

Phase 1 · small molecule · Synovial Sarcoma

CFT8634 for Synovial Sarcoma is a Phase 1 program (small_molecule) at C4 Therapeutics with 1 ClinicalTrials.gov record(s).

← All C4 Therapeutics projects Phase 1 small molecule terminated

Internal code CFT8634-1101

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
C4 Therapeutics
Phase
Phase 1
Modality
small_molecule
Indication
Synovial Sarcoma
Status
terminated
Trials
1

Clinical trials